Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on March 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(6):382-386; doi:10.1093/jnci/djn071
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/6/382    most recent
djn071v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Personal Genetic Tests Facing Scrutiny

Charlie Schmidt

The first 150 words of the full text of this article appear below.

Seven years ago, the decoding of the human genome was followed by a publicity blitz that triggered high expectations for personalized medicine. Now companies have begun to cash in on those expectations by offering genetic tests for everything from cancer risk to family ancestry—even athletic prowess. A recent survey by Stuart Hogarth, a research epidemiologist with the University of Cambridge in the United Kingdom, finds that 27 companies—most of them based in the United States—are selling genetic tests directly to consumers through the Internet for costs ranging from hundreds to thousands of dollars.

But the rush to market genetic tests has been met with skepticism from within the scientific community. Experts increasingly warn that the science behind these tests may not be ready for prime time: The tests’ appearance now poses worrisome consequences, not just for consumer safety but also for the public's trust in personalized medicine. "Consumers may be . . . [Full Text of this Article]

Adapting to Genomic Realities

Quality Concerns Grow

Inadequate Regulations?

Dealing With Clinical Validity

Prostate Cancer Test Combines Gene Variants To Predict Risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?